Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells $20,788.70 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRKGet Free Report) insider Mo Qatanani sold 2,315 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $8.98, for a total value of $20,788.70. Following the completion of the transaction, the insider now owns 144,704 shares in the company, valued at approximately $1,299,441.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Scholar Rock Stock Performance

Shares of Scholar Rock stock opened at $8.30 on Friday. The stock has a 50 day moving average price of $12.12 and a two-hundred day moving average price of $14.81. The company has a quick ratio of 6.58, a current ratio of 6.58 and a debt-to-equity ratio of 0.24. Scholar Rock Holding Co. has a 12-month low of $5.93 and a 12-month high of $21.17.

Scholar Rock (NASDAQ:SRRKGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11). During the same quarter in the previous year, the company earned ($0.46) EPS. As a group, equities analysts predict that Scholar Rock Holding Co. will post -2.4 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SRRK. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Scholar Rock in a report on Tuesday, June 4th. Piper Sandler reissued an “overweight” rating and issued a $28.00 price target on shares of Scholar Rock in a research note on Tuesday, March 26th. BMO Capital Markets boosted their price target on Scholar Rock from $29.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, June 13th. Raymond James assumed coverage on Scholar Rock in a research note on Thursday, March 28th. They issued a “strong-buy” rating and a $30.00 price target for the company. Finally, Truist Financial reissued a “buy” rating and issued a $20.00 price target on shares of Scholar Rock in a research note on Wednesday, April 3rd. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $26.00.

View Our Latest Analysis on Scholar Rock

Hedge Funds Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRRK. Polar Capital Holdings Plc bought a new stake in shares of Scholar Rock during the third quarter valued at approximately $10,664,000. Price T Rowe Associates Inc. MD increased its position in shares of Scholar Rock by 16.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,321,471 shares of the company’s stock valued at $156,444,000 after purchasing an additional 1,149,519 shares during the period. Eventide Asset Management LLC bought a new stake in shares of Scholar Rock during the fourth quarter valued at approximately $18,287,000. Goldman Sachs Group Inc. increased its position in shares of Scholar Rock by 31.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,430,764 shares of the company’s stock valued at $26,898,000 after purchasing an additional 342,690 shares during the period. Finally, Redmile Group LLC increased its position in shares of Scholar Rock by 7.5% during the third quarter. Redmile Group LLC now owns 4,733,248 shares of the company’s stock valued at $33,606,000 after purchasing an additional 329,408 shares during the period. 91.08% of the stock is currently owned by institutional investors.

About Scholar Rock

(Get Free Report)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Featured Stories

Insider Buying and Selling by Quarter for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.